US Pharma MarketingRevMed's cancer drug feels out of reach for some, SCOTUS preserves key generic drug pathway, and more biotech news Cancer HHS CMS Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home The Readout Will Makary’s FDA voucher program survive? RevMed’s cancer drug feels out of reach for some,…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Even though RevMed’s experimental pancreatic cancer drug, daraxonrasib, hasn’t yet achieved approval, it is available through an expanded access program. But that doesn’t mean getting it is easy.
Source: STAT News Pharma